ERBB2 and breast carcinoma: An 111In-labeled F3 peptide (Peptides, Figure 2), which is a fragment of the human high mobility group protein 2-binding nucleolin, was developed to investigate the Auger electron-targeted radiotherapy in HER2-positive breast cancer xenograft models (Cornelissen et al., 2012).